1952 Stock Overview
A biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Everest Medicines Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$38.75 |
| 52 Week High | HK$39.95 |
| 52 Week Low | HK$14.34 |
| Beta | 1.94 |
| 11 Month Change | 13.30% |
| 3 Month Change | 84.52% |
| 1 Year Change | 78.16% |
| 33 Year Change | 1.31% |
| 5 Year Change | n/a |
| Change since IPO | -57.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1952 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 12.3% | -0.3% | -0.6% |
| 1Y | 78.2% | -15.2% | 9.6% |
Return vs Industry: 1952 exceeded the Hong Kong Biotechs industry which returned -15.2% over the past year.
Return vs Market: 1952 exceeded the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 1952 volatility | |
|---|---|
| 1952 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1952 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1952's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 432 | Rogers Luo | www.everestmedicines.com |
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases.
Everest Medicines Limited Fundamentals Summary
| 1952 fundamental statistics | |
|---|---|
| Market cap | HK$12.46b |
| Earnings (TTM) | -HK$1.13b |
| Revenue (TTM) | HK$449.57m |
27.7x
P/S Ratio-11.0x
P/E RatioIs 1952 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1952 income statement (TTM) | |
|---|---|
| Revenue | CN¥418.55m |
| Cost of Revenue | CN¥101.53m |
| Gross Profit | CN¥317.02m |
| Other Expenses | CN¥1.37b |
| Earnings | -CN¥1.05b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.28 |
| Gross Margin | 75.74% |
| Net Profit Margin | -251.64% |
| Debt/Equity Ratio | 10.9% |
How did 1952 perform over the long term?
See historical performance and comparison